期刊文献+

纳米递药系统治疗阿尔茨海默病的研究进展 被引量:2

在线阅读 下载PDF
导出
摘要 阿尔茨海默病(Alzheimer’sdisease.AD)是一种进展性的神经退行性疾病,也是痴呆最常见的类型。AD目前尚无有效的治疗方法,其中重要的原因就是治疗AD的药物无法有效的通过血脑屏障(bloodbrainbarrier,BBB)。纳米递药系统以其独特的优势,成为目前可以通过BBB治疗AD最有希望的手段。通过纳米介导递药系统治疗AD目前已经取得了一定的进展,然而由于其脑靶向性不高从而受到极大的限制。
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2012年第9期561-564,共4页 Chinese Journal of Nervous and Mental Diseases
基金 国家自然基金项目(编号:81000466)
作者简介 通讯作者:刘中霖,E-mail:zhonglinliu@126.com.
  • 相关文献

参考文献40

  • 1曾凡,张吉强,王延江.体液生物标记物在阿尔茨海默病早期诊断中的作用与评价[J].中国神经精神疾病杂志,2011,37(4):244-246. 被引量:13
  • 2Pardridge WM. Alzheimer's disease drug development and the problem of the blood-brain barrier[J]. Alzheimers Dement, 2009,5(5) :427-432.
  • 3Di Stefano A, Iannitelli A, Laserra S, et al. Drug delivery strategies for Alzheimer's disease treatment [J ]. Expert Opin Drug Deliv,20l1,8(5) :581-603.
  • 4Sahni J K, Doggui S, Ali J, et al. Neurotherapeutic applica- tions of nanoparticles in Alzheimer's disease[Jl. J Control Re- lease, 2011,152 (2) : 208-231.
  • 5Faraji AH, Wipf P. Nanoparticles in cellular drug delivery[J]. Bioorg Med Chem, 2009,17 ( 8 ) : 2950-2962.
  • 6Celia C, Cosco D, Paolino D, et al. Nanoparticulate devices for brain drug delivery [J]. Med Res Rev, 2011,5 (41) : 716- 756.
  • 7Limbach LK, Wick P, Manser P, et al. Exposure of engi- neered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress [ J ]. Environ Sci Technol, 2007,41 ( 11 ) : 4158-4163.
  • 8Leitner I, Nemeth J, Feurstein T, et al. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial mul- tidrug resistance by increasing intracellular drug concentration [J]. J Antimicroh Chemother, 2011,66(4) : 834-839.
  • 9Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma ceils [J]. J Liposome Res, 2002,12(4) : 301-309.
  • 10Abbott N J, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier [J]. Neurobiol Dis,2010,37 (1):13-25.

二级参考文献51

  • 1彭丹涛,许贤豪,孟晓梅,刘江红,谢琰臣,冯凯.老年性痴呆血浆中Aβ1-42、Aβ1-40及p-tau(^(181)P)蛋白的临床诊断意义[J].中国神经免疫学和神经病学杂志,2005,12(4):208-211. 被引量:13
  • 2Lanari A,Parnetti L.Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment:4-year follow-up in a routine clinical setting[J].Scientific World-Journal,2009,9:961-966.
  • 3Irizarry MC.Biomarkers of Alzheimer disease in plasma[J].NeuroRx,2004,1(2):226-234.
  • 4Lewczuk P,Kornhuber J,Vanmechelen E,et al.Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease:A multicenter study with multiplexing[J].Exp Neurol,2010,223(2):366-370.
  • 5Gustaw K A,Garrett MR,Lee HG,et al.Antigen-antibody dissociation in Alzheimer disease:a novel approach to diagnosis[J].J Neurochem,2008,106(3):1350-1356.
  • 6Gustaw-Rothenberg K A,Siedlak SL,Bonda DJ,et al.Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease:a population-based study[J].Exp Gerontol,2010,45(1):47-52.
  • 7Goodman I,Golden G,Flitman S,,et al.A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease[J].J Am Med Dir Assoc,2007,8(1):21-30.
  • 8Yamagishi S,Nakamura K,Imaizumi T.Advanced glycation end products(AGEs) and diabetic vascular complications[J].Curr Diabetes Rev,2005,1(1):93-106.
  • 9Takeuchi M,Sato T,Takino J,et al.Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products(TAGE) in early detection of Alzheimer's disease[J].Med Hypotheses,2007,69(6):1358-1366.
  • 10Leszek J,Malyszczak K,Bartys A,et al.Analysis of serum of patients with Alzheimer's disease for the level of advanced glycation end products[J].Am J Alzheimers Dis Other Demen,2006,21(5):360-365.

共引文献13

同被引文献38

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部